Fig. 4.

Aurora kinase B inhibitor enhanced the efficacy of immunotherapy in MC38/gp100 tumor model. a Regimen by which mice received the combination of 25 mg/kg Aurora kinase B inhibitor AZD1152 and 100 µg of anti-CTLA4 checkpoint blockade immunotherapy. b Although AZD1152 by itself did not significantly decrease tumor growth (p = 0.361), the combination of AZD1152 and anti-CTLA4 significantly reduced tumor growth compared with AZD1152 (p < 0.001) or anti-CTLA4 (p = 0.019) alone (Fig. 4b). Size differences between the groups were analyzed by repeated measures analysis of variance. c Kaplan–Meier curves and log-rank analysis showed that treatment with the combination of AZD1152 and anti-CTLA4 resulted in significantly improved survival (p = 0.002). N = 5 per group; the data are representative of two independent experiments: *p < 0.05; **p < 0.01; ***p < 0.001